



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/284,578	10/08/1999	AKIKO MIYA	325/E6627	2522
7590 01/11/2006		EXAMINER		
WENDEROTH LIND & PONACK 2033 K STREET NW			WEBMAN, EDWARD J	
SUITE 800			ART UNIT	PAPER NUMBER
WASHINGTON, DC 20006			1616	
		1010		

DATE MAILED: 01/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)		
Office Action Summary		09/284,578	MIYA ET AL.		
		Examiner	Art Unit		
		Edward J. Webman	1616		
The MAILI Period for Reply	NG DATE of this communication app	ears on the cover sheet with the c	orrespondence address		
A SHORTENED OF WHICHEVER IS Extensions of time may after SIX (6) MONTHS If NO period for reply	STATUTORY PERIOD FOR REPLY LONGER, FROM THE MAILING DA ay be available under the provisions of 37 CFR 1.13 of from the mailing date of this communication. is specified above, the maximum statutory period we the set or extended period for reply will, by statute,	ATE OF THIS COMMUNICATION (16(a). In no event, however, may a reply be time till apply and will expire SIX (6) MONTHS from (18).	N. nely filed the mailing date of this communication.		
earned patent term ac	the Office later than three months after the mailing tjustment. See 37 CFR 1.704(b).	date of this communication, even if timely filed	, may reduce any		
Status					
· = ·	e to communication(s) filed on <u>03 Se</u>				
<u> </u>	This action is FINAL . 2b) This action is non-final.				
•	application is in condition for allowan				
Closed III at	ccordance with the practice under E	x parte Quayle, 1955 C.D. 11, 45	5 O.G. 213.		
Disposition of Clain	ıs				
4a) Of the a 5) ☐ Claim(s) 6) ☑ Claim(s) 1- 7) ☐ Claim(s)	4,30 and 31 is/are pending in the apabove claim(s) is/are withdraw is/are allowed. 4,30 and 31 is/are rejected. is/are objected to. are subject to restriction and/or	vn from consideration.			
Application Papers					
10) The drawing Applicant ma	ration is objected to by the Examiner g(s) filed on is/are: a) access ay not request that any objection to the cut drawing sheet(s) including the correction declaration is objected to by the Examiner.	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).		
Priority under 35 U.	S.C. § 119				
a) All b) Certii 2. Certii 3. Copie applii	iment is made of a claim for foreign in Some * c) None of: fied copies of the priority documents fied copies of the priority documents es of the certified copies of the priorication from the International Bureau ched detailed Office action for a list of	have been received. have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage		
Attachment(s)					
	on's Patent Drawing Review (PTO-948) ure Statement(s) (PTO-1449 or PTO/SB/08)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:			

Art Unit: 1616

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4, 30 are rejected under 35 U.S.C. 102(b) as being anticipated by Guiere.

Guire teaches a solid surface modified with a linker covalently bound to the surface by photo activation of one linking group, the other linking group being bound to a biocompatible agent (abstract). Antibiotics are specified (column 6 line 160, including penicillin (claim 6). A linker comprising polyoxyethylene is disclosed (column 6 line 26). A linkage of a carboxyl group to nitrogen or oxygen is specified (column 7 lines 36-39). Polyolefins are specified as a substrate (column 4 line 33).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-4, 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Patnaik et al '165.

Patnaik et al '165 teach a PTFE backbone bound to a polymeric spacer with amine terminal bonds which is in turn bound to a bioactive molecule (abstract, column 4

Art Unit: 1616

lines 54-59). An amide bond is specified (column 5 lines 1-5). Antibiotics are disclosed (column 6 line 29). Polymeric spacers are disclosed (column 5 lines 54-59).

The examiner takes notice under MPEP 2144.03 that both penicillin, lymecycline and benanomicin contain carboxylic acid group.

It would have been obvious to one of ordinary skill to attach penicillin, lymecycline or benanomicin to the polymer o of Patnaik et al '166 in view of the fact that they contain a carboxylic acid group which can be reacted with the amine terminated spacer of Patnaik et al '165.

Claims 1-4, 30 are rejected under 35 U.S.C. 102(b) as being anticipated by Goldberg et al.

Goldberg et al teach a surface graft-polymerized with a monomer wherein a biofunctional agent is chemically bonded (abstract). Substrates include polyolefins (column 15 line 1). Monomers with ethylenic unsaturation containing carboxylic acid and amine moieties are specified (column 12 lines 46-67). Penicillin and tetracycline are disclosed (column 17 lines 56-57).

Regarding Guire and Patnaik '165, applicants argue graft polymerization deep inside the substrate by the claimed method, the presence of grafted chains unbound to antibiotic inside the substrate, subsequent "expansion of these (unbound) chains" upon hydration which results in more mobility of chains with antibiotics bound at the substrate surface. However, applicants claim a substrate of any thickness. Such expansion is irrelevant with a thin substrate. Further, applicants do not claim partial binding of the

antibiotics. Regarding Goldberg et al, applicants stipulate that deep penetrating grafted

chains will be created, but the number of chains will be less than with the claimed

process. However, applicants claim no limitation regarding the percentage of deep

penetrating chains. Lastly, it is unclear that applicants' inventive contemplated the

creation of deeply penetrating grafted chains unbound to antibiotic because the

disclosure does not appear to explicate such creation.

Claims 1-4, 30, 31 are rejected under 35 U.S.C. 102(b) as being anticipated by

Calcaterra et al

Calcaterra et al teach graft copolymerization via electron beam irradiation of a

functionalized vinyl monomer onto a base fabric, followed by reaction of the functional

group with an animicbrobial with formation of a covalent bond (abstract). Polyolefins

are specified (column 6 line 51). Vinyl monomers containing amines and carboxylic

acids are specified (column 7 lines 6-22). Macrolide antibiotics are specified (column 10

line 4). Preirradiation is disclosed (column 8 lines 13-15). Regarding the claimed

exposure to monomers in the gas phase, such a process limitation is not considered

patentable during prosecution of a composition claim before the USPTO.

No claims allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in

this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP

§ 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37

CFR 1.136(a).

Art Unit: 1616

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Edward J. Webman whose telephone number is 571-272-0633. The examiner can normally be reached on M-F from 8 AM to 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, S. Padmanabhan, can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

Art Unit: 1616

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

EDWARD J. WEBMAN PRIMARY EXAMINER GROUP 1500 Page 6